Skip to content

An Educational Self-tracking Tool for Identification of SARS-CoV-2 Risk Transmission

An Educational Self-tracking Tool for Identification of SARS-CoV-2 Risk Transmission: a Randomised Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05171829
Acronym
TrackU
Enrollment
180
Registered
2021-12-29
Start date
2021-12-27
Completion date
2022-05-15
Last updated
2021-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Empowerment, Sars-CoV-2 Infection, Transmission

Brief summary

One way to empower a community, in epidemic control issues, is to know the first-hand screening tools. There are no evaluations of these home-use tools from the perspective of patient and citizen empowerment and participation. The main objective of this study is to analyze whether a self-tracking and self-tracing tool, developed in a participatory way, increases the risk identification of the disease and the empowerment in terms of risk management of transmission by the participants.

Interventions

OTHERTrack U

Track U diary

Sponsors

Escoles Universitaries Gimbernat
CollaboratorOTHER
University of Barcelona
CollaboratorOTHER
Barcelona Institute for Global Health
CollaboratorOTHER
Universitat Politècnica de Catalunya
CollaboratorOTHER
Universitat Oberta de Catalunya
CollaboratorOTHER
Hospital Clinic of Barcelona
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Masking description

Statistician masking

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Fluent in Catalan or Spanish, Resident in Catalonia, Signs informed consent, Commitment to use the tool if he/she gets in intervention group.

Exclusion criteria

Language barrier and other conditions that do not allow self-completion of the survey Be a COVID case or contact at the time of recruitment.

Design outcomes

Primary

MeasureTime frameDescription
Risk identification of SARS-CoV 2 transmission17 daysRisk identification of SARS-CoV 2 transmission

Secondary

MeasureTime frameDescription
Empowerment in SARS-CoV 2 transmission17 daysEmpowerment in SARS-CoV 2 transmission

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026